Instil Bio, INC. (TIL) — SEC Filings

Overview

Instil Bio, INC. (TIL) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a S-8 filed on Mar 27, 2026: Instil Bio, Inc. filed an S-8 form on March 27, 2026, registering an unspecified number of securities to be offered under its employee benefit plans. This filing indicates the company is making shares available for its employees, likely as part of compensation or incentive programs. The filing does

Sentiment Summary

Across 37 filings, the sentiment breakdown is: 2 bearish, 33 neutral, 2 mixed. The dominant filing sentiment for Instil Bio, INC. is neutral.

Filing Type Overview

Instil Bio, INC. (TIL) has filed 19 8-K, 1 S-8, 3 10-K, 6 10-Q, 1 DEF 14A, 3 SC 13G/A, 1 SC 13D/A, 3 SC 13G with the SEC between Jan 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (37)

• 8-K Filing — 8-K · Apr 3, 2026
• Instil Bio Files S-8 for Employee Stock Plan — S-8 · Mar 27, 2026 Risk: low
  Instil Bio, Inc. filed an S-8 form on March 27, 2026, registering an unspecified number of securities to be offered under its employee benefit plans. This filin
• Instil Bio Scraps Lead Drug, Faces Going Concern Doubts — 10-K · Mar 27, 2026 Risk: high
  Instil Bio, Inc. (TIL) reported significant strategic shifts and financial challenges for the fiscal year ended December 31, 2025. The company announced in Janu
• 8-K Filing — 8-K · Mar 27, 2026
• Instil Bio Narrows Q3 Loss, Boosts R&D Amid Asset Sale — 10-Q · Nov 13, 2025 Risk: high
  Instil Bio, Inc. reported a net loss of $13.587 million for the three months ended September 30, 2025, a significant improvement from the $23.021 million net lo
• Instil Bio's Losses Widen Amid R&D Costs, Tarzana Facility Sale — 10-Q · Aug 13, 2025 Risk: high
  Instil Bio, Inc. reported a net loss of $21.394 million for the three months ended June 30, 2025, an increase from $14.917 million in the prior year period, and
• Instil Bio Files 8-K: Other Events Reported — 8-K · Jul 31, 2025 Risk: medium
  Instil Bio, Inc. filed an 8-K on July 31, 2025, to report "Other Events." The filing does not contain specific details about the nature of these events, dollar
• Instil Bio Files 8-K on Security Holder Vote Matters — 8-K · May 28, 2025 Risk: low
  Instil Bio, Inc. filed an 8-K on May 28, 2025, to report on a submission of matters to a vote of security holders. The filing does not contain specific details
• Instil Bio Files 8-K — 8-K · May 27, 2025 Risk: medium
  Instil Bio, Inc. filed an 8-K on May 27, 2025, reporting events that occurred on May 22, 2025. The filing pertains to Regulation FD Disclosure, Other Events, an
• Instil Bio Files 8-K for Disclosure and Exhibits — 8-K · May 22, 2025 Risk: low
  Instil Bio, Inc. filed an 8-K on May 22, 2025, to report a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain specific
• Instil Bio Files Q1 2025 10-Q — 10-Q · May 13, 2025 Risk: medium
  Instil Bio, Inc. filed its Q1 2025 10-Q report on May 13, 2025, detailing its financial position as of March 31, 2025. The company, operating in the biological
• Instil Bio Sets May 28th Annual Meeting — DEF 14A · Apr 14, 2025 Risk: low
  Instil Bio, Inc. filed its definitive proxy statement for the annual meeting of stockholders to be held on May 28, 2025. The company, located at 3963 Maple Aven
• Instil Bio Files 8-K for Material Agreement — 8-K · Mar 31, 2025 Risk: low
  Instil Bio, Inc. filed an 8-K on March 28, 2025, reporting a material definitive agreement and financial statements. The filing details Instil Bio's corporate i
• 10-K Filing — 10-K · Mar 4, 2025
• Instil Bio Files 8-K with Corporate Updates — 8-K · Jan 14, 2025 Risk: low
  Instil Bio, Inc. filed an 8-K on January 14, 2025, reporting other events and financial statements. The filing details the company's principal executive offices
• Instil Bio Secures $150M Credit Facility, Terminates Prior Agreement — 8-K · Dec 23, 2024 Risk: medium
  Instil Bio, Inc. announced on December 20, 2024, the termination of a material definitive agreement and the creation of a direct financial obligation. The compa
• SC 13G/A Filing — SC 13G/A · Nov 14, 2024
• SC 13G/A Filing — SC 13G/A · Nov 14, 2024
• Instil Bio Files Q3 2024 10-Q — 10-Q · Nov 13, 2024 Risk: medium
  Instil Bio, Inc. filed its 10-Q for the period ending September 30, 2024. The filing details financial performance and operational updates for the third quarter
• SC 13G/A Filing — SC 13G/A · Oct 25, 2024
• Curative Ventures V LLC Amends Instil Bio Stake Filing — SC 13D/A · Oct 22, 2024 Risk: medium
  Curative Ventures V LLC, through an amendment filed on October 22, 2024, has updated its Schedule 13D regarding its holdings in Instil Bio, Inc. The filing indi
• SC 13G Filing — SC 13G · Sep 27, 2024
• SC 13G Filing — SC 13G · Sep 27, 2024
• Instil Bio Files 8-K with Regulatory Updates — 8-K · Sep 16, 2024 Risk: low
  Instil Bio, Inc. filed an 8-K on September 16, 2024, reporting on various events. The filing includes information related to Regulation FD Disclosure, Other Eve
• Instil Bio Reports Exit/Disposal Costs — 8-K · Sep 6, 2024 Risk: medium
  Instil Bio, Inc. filed an 8-K on September 6, 2024, reporting costs associated with exit or disposal activities as of September 1, 2024. The filing does not spe
• Instil Bio Files 8-K — 8-K · Aug 15, 2024 Risk: medium
  Instil Bio, Inc. filed an 8-K on August 15, 2024, to report a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain specif
• Instil Bio, Inc. Files Q2 2024 10-Q Report — 10-Q · Aug 13, 2024 Risk: medium
  Instil Bio, Inc. filed its 10-Q report for the quarterly period ended June 30, 2024. The company is incorporated in Delaware and its principal executive offices
• Instil Bio Enters Material Definitive Agreement — 8-K · Aug 1, 2024 Risk: medium
  Instil Bio, Inc. filed an 8-K on August 1, 2024, to report the entry into a material definitive agreement. The filing does not provide specific details about th
• Instil Bio Enters Material Definitive Agreement — 8-K · Jul 11, 2024 Risk: medium
  Instil Bio, Inc. announced on July 10, 2024, that it has entered into a Material Definitive Agreement. The filing does not provide specific details about the na
• Instil Bio, Inc. Files 8-K on Shareholder Votes — 8-K · Jun 17, 2024 Risk: low
  Instil Bio, Inc. filed an 8-K on June 17, 2024, reporting on matters submitted to a vote of security holders as of June 13, 2024. The filing details the company
• Instil Bio, Inc. Files 10-Q for Q1 2024 — 10-Q · May 10, 2024 Risk: low
  Instil Bio, Inc. (TIL) filed a Quarterly Report (10-Q) with the SEC on May 10, 2024. Instil Bio, Inc. filed its 10-Q for the period ending March 31, 2024. The f
• Instil Bio Board Changes and Officer Compensation — 8-K · Apr 26, 2024 Risk: medium
  Instil Bio, Inc. announced on April 24, 2024, the departure of Director David M. Earp and the election of new directors, including Dr. Jeffrey J. Ryan and Dr. D
• SC 13G Filing — SC 13G · Apr 2, 2024
• Instil Bio, Inc. Files 2023 Annual Report on Form 10-K — 10-K · Mar 21, 2024 Risk:
  Instil Bio, Inc. (TIL) filed a Annual Report (10-K) with the SEC on March 21, 2024. Instil Bio, Inc. filed its 2023 Form 10-K on March 21, 2024, reporting on it
• Instil Bio Files 8-K on Officer Changes & Compensation — 8-K · Feb 14, 2024 Risk: low
  Instil Bio, Inc. filed an 8-K on February 14, 2024, reporting an event that occurred on February 12, 2024. The filing concerns the departure, election, or appoi
• Instil Bio 8-K: Administrative Update, Confirms Emerging Growth Status — 8-K · Jan 18, 2024
  Instil Bio, Inc. filed an 8-K on January 18, 2024, reporting an 'Other Event' that occurred on January 17, 2024. This filing primarily updates administrative in
• Instil Bio Reports Exit/Disposal Activities on Jan 14 — 8-K · Jan 16, 2024
  Instil Bio, Inc. filed an 8-K on January 16, 2024, reporting an event on January 14, 2024, related to 'Cost Associated with Exit or Disposal Activities' and 'Ot

Risk Profile

Risk Assessment: Of TIL's 25 recent filings, 3 were flagged as high-risk, 12 as medium-risk, and 10 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.

Key Executives

• Chief Executive Officer
• BRONSON CROUCH
• David M. Earp
• Dr. Jeffrey J. Ryan

Industry Context

The biotechnology sector is highly competitive and driven by rapid scientific advancements and intellectual property. Companies like Instil Bio face intense competition from established pharmaceutical giants and emerging biotech firms, many of whom possess superior financial and R&D resources. Success hinges on innovation, strategic partnerships, and navigating complex regulatory pathways.

Top Tags

8-K (5) · financials (5) · Biotechnology (4) · corporate-governance (4) · 10-Q (4) · sec-filing (3) · SEC Filing (3) · Clinical Trials (2) · Oncology (2) · Cash Burn (2)

Key Numbers

• aggregate market value of common stock held by non-affiliates: $83.4 million — as of June 30, 2025, indicating market valuation
• closing price per share: $20.83 — on June 30, 2025, used to calculate market value
• Common Stock outstanding: 6,781,976 shares — as of March 25, 2026
• date of AXN-2510 discontinuation: January 2026 — marks a significant strategic shift
• date AXN-2510 was in-licensed: August 2024 — short duration of the licensing agreement
• Net loss (Q3 2025): $13.587M — Decreased from $23.021M in Q3 2024
• Net loss (9 months ended Sep 30, 2025): $63.181M — Slightly increased from $62.240M in 9 months ended Sep 30, 2024
• Research and development expenses (Q3 2025): $9.127M — Increased from $562K in Q3 2024
• Assets held for sale (Sep 30, 2025): $112.096M — Represents the Tarzana facility
• Impairment of long-lived assets (9 months ended Sep 30, 2025): $16.6M — Related to the Tarzana facility
• Cash and cash equivalents (Sep 30, 2025): $5.801M — Decreased from $8.805M at Dec 31, 2024
• Marketable securities (Sep 30, 2025): $73.867M — Decreased from $104.510M at Dec 31, 2024
• Proceeds from at-the-market offering (9 months ended Sep 30, 2025): $6.611M — Net of issuance costs
• Shares of Common Stock outstanding (Nov 11, 2025): 6,781,976 — Increased from 6,525,887 at Dec 31, 2024
• Net loss per share (Q3 2025): $2.01 — Improved from $3.54 in Q3 2024

Related Companies

ISRB

Frequently Asked Questions